Clinical trials: insulin glargine
Type 2 Diabetes
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
Primary objective: Efficacy assessment of the percentage of positive responders patients receiving Lantus plus glucophage association.
- Trial name
- GALATEE (NCT00653302)
- Testing
- Lantus (insulin glargine) + Glucophage (Metformin)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
The primary objective of this study is to show that a prandial insulin regimen, consisting of premeal insulin lispro "mid mixture" (or a combined regimen of insulin lispro "mid mixture" and insulin lispro "low mixture") plus…
- Trial name
- NCT00191464
- Testing
- premeal insulin lispro mixtures, insulin glargine, metformin
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glulisine in Type 2 Diabetic Patients
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled…
- Trial name
- Basal Plus (NCT00360698)
- Testing
- Insulin Glargine, Glimepiride, Insulin Glulisine
- Where
- 3 sites in United States, Russia and 1 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-O1 (NCT02749890)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Lixisenatide (AVE0010), Oral anti-diabetic drugs
- Where
- 61 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising iGlarLixi, metformin, and lifestyle approaches will be superior to standard…
- Trial name
- REMIT-iGL (NCT03130426)
- Testing
- iGlarLixi, Insulin Glargine, Metformin
- Where
- 8 sites in Canada
- Volunteers
- 161 people
- Sponsor
- Population Health Research Institute
Diabetes Mellitus, Type II
Comparison of Apidra to Regular Insulin in Hospitalized Patients
The purpose of this study is to compare Apidra (a rapid acting insulin analogue) with Regular insulin (fast acting) in addition to the use of long acting insulin Glargine in hospitalized patients in terms of efficacy and safety…
- Trial name
- Apidra (NCT00528918)
- Testing
- Glulisine (Apidra)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Carl T. Hayden VA Medical Center
Type I Diabetes
Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh
This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh
- Trial name
- NCT06674135
- Testing
- biosimilar insulin glargine
- Where
- Bangladesh
- Volunteers
- 202 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Diabetes Mellitus, Type 2
Lantus Versus Levemir Treat-To-Target
Primary objective: To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not…
- Trial name
- L2T3 (NCT00405418)
- Testing
- Insulin glargine, Insulin Detemir
- Where
- 20 sites in Australia, Brazil and 18 more
- Volunteers
- 973 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
- Trial name
- NCT06716424
- Testing
- iGlarLixi (insulin glargine/lixisenatide)
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
This is a two-centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over study using a standardised solid meal test in subjects with type 2 diabetes to investigate postprandial glucose control of…
- Trial name
- NCT02915250
- Testing
- BioChaperone® Combo, Humalog® Mix25, Humalog®
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo
Primary Objective: To demonstrate the non-inferiority of the MyStar DoseCoach (Long-acting Insulin Glargine Titration Meter) device-supported treat-to-target regimen relative to a routine titration regimen in the percentage of…
- Trial name
- AUTOMATIX (NCT02585674)
- Testing
- Insulin glargine (U300), MyStar DoseCoach
- Where
- 19 sites in Germany, United Kingdom
- Volunteers
- 151 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Apidra Children & Adolescents Study
Primary Objective: Evaluate the percentage of patients achieving glycosylated hemoglobin (HbA1c) level < 8% (in patients of 6-12 years old) and HbA1c level < 7.5% (in patients of 13-17 year old) at 6 and 12 months of treatment…
- Trial name
- NCT01202474
- Testing
- INSULIN GLULISINE, INSULIN GLARGINE
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sanofi
Type 2 Diabetes
Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines
The obesity and type 2 diabetes mellitus (T2DM) are among the most threatening health crisis for the 21st century. Currently, it is estimated that there are 205 million people with T2DM worldwide.
- Trial name
- PRODIGIES (NCT01974544)
- Testing
- Best medical treatment, gastric bypass, sleeve gastrectomy
- Where
- Chile
- Volunteers
- 150 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Type 2 Diabetes Mellitus
Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
The purpose of this study is to compare the efficacy of Amaryl®M 1/500 mg twice daily versus Amaryl® 4 mg both in combination with Lantus® once-daily regimen in type 2 Diabetes Mellitus patients with inadequate glycemic control.
- Trial name
- NCT00913367
- Testing
- glimepiride + insulin glargine (Amaryl + Lantus), glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
Insulin Therapy in the Hospital Comparing Two Protocols
The purpose of this study is to determine if by using insulin analog (Glargine and lispro insulin) with an insulin pen the investigators are able to obtain a higher rate of correct timing of insulin and food administration as…
- Trial name
- NCT00841919
- Testing
- Glargine insulin, NPH insulin and regular insulin, lispro insulin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cook County Health
Efficacy, Self, Adverse Effect
Efficacy and Safety of Weight-Based Insulin Titration Regimen in Hospitalized Patients With Type 2 Diabetes
The investigators propose to use a weight-based regimen consisting of basal-bolus insulin and preprandial rapid-acting insulin and to test its efficacy and safety in controlling blood glucose in hospitalized patients with type 2…
- Trial name
- WEB-IT (NCT03220919)
- Testing
- Weight-based, Glucose level-based
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Type 2 Diabetes
Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes
Glucose-induced insulin secretion is often diminished in hyperglycaemic patients with type 2 diabetes. The investigators examined, whether chronic basal insulin treatment with insulin glargine lead to improvements in…
- Trial name
- NCT01249677
- Testing
- insulin glargine
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Ruhr University of Bochum
Diabetes Mellitus, Type 1
A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is…
- Trial name
- NCT03723772
- Testing
- Insulin icodec, IGlar U100
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company